myVax™ - Intelligent, Patient-centered Health Platform

CDC NEWS

Latest News

Coronavirus (COVID-19) Update: FDA Takes Additional Actions on the Use of a Booster Dose for COVID-19 Vaccines

20 Oct 2021

Today, the U.S. Food and Drug Administration took action to expand the use of a booster dose for COVID-19 vaccines in eligible populations. The agency is amending the emergency use authorizations (EUA) for COVID-19 vaccines to allow for the use of a single booster dose as follows: The use of a single booster dose of the Moderna COVID-19 Vaccine that may be administered at least 6 months after completion of the primary series to individuals: 65 years of age and older 18 through 64 years of age at high risk of severe COVID-19 18 through 64 years of age with frequent institutional or occupational exposure to SARS-CoV-2

COVID-19 Vaccines Protect the Family, Too

19 Oct 2021

Any of the available COVID-19 vaccines offer remarkable personal protection against the coronavirus SARS-CoV-2. So, it also stands to reason that folks who are vaccinated will reduce the risk of spreading the virus to family members within their households. That protection is particularly important when not all family members can be immunized—as when there are children under age 12 or adults with immunosuppression in the home. But just how much can vaccines help to protect families from COVID-19 when only some, not all, in the household have immunity?

COVID super-immunity: one of the pandemic’s great puzzles

15 Oct 2021

People who have previously recovered from COVID-19 have a stronger immune response after being vaccinated than those who have never been infected. Scientists are trying to find out why.

If You’ve Had Covid, Do You Need the Vaccine?

12 Oct 2021

So-called natural immunity varies from patient to patient, scientists say. Immunization is still the best choice after recovering from the disease.

Pfizer Asks F.D.A. to Authorize Its Covid-19 Vaccine for Children 5 to 11

07 Oct 2021

WASHINGTON — Pfizer and BioNTech said on Thursday morning that they had asked federal regulators to authorize emergency use of their coronavirus vaccine for children ages 5 to 11, a move that could help protect more than 28 million people in the United States.

SARS-CoV-2 Vaccines

26 Feb 2021

Shortly after SARS-CoV emerged at the turn of the 21st century, the spike (S) protein (particularly in its prefusion [native] conformation) was identified as the immunodominant antigen of the virus. Evaluation of patients with SARS-CoV-2 revealed that binding and neutralizing antibodies primarily target the receptor-binding domain of the S1 subunit.

SARS-CoV-2 Variants of Concern in the United States—Challenges and Opportunities

17 Feb 2021

. SARS-CoV-2, like other RNA viruses, constantly changes through mutation, with new variants occurring over time. Generally, when new variants become more common, they do so because of some selective advantage to the virus.

The US Regulatory System and COVID-19 Vaccines The Importance of a Strong and Capable FDA

15 Feb 2021

For many in public health and medicine, the coronavirus disease 2019 (COVID-19) pandemic in the US has been a frustrating journey from one disappointment to the next: late access to testing, insufficient staff and inadequate funding for contact tracing, jumbled communications, and, at the end of 2020, a chaotic launch of vaccination efforts.

COVID-19 Vaccination in Pregnant and Lactating Women

08 Feb 2021

Pregnant women with severe or critical coronavirus disease 2019 (COVID-19) infection are at increased risk for preterm birth and pregnancy loss.

Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination

04 Feb 2021

We recently reported the results of a phase 1 trial of a messenger RNA vaccine, mRNA-1273, to prevent infection with SARS-CoV-2; those interim results covered a period of 57 days after the first vaccination.